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Abstract
Background: Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer’s disease (AD) and other
dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD prevalence
across international cohorts.
Methods: We combined individual participant data for 16 cohorts from 15 countries (members of the COSMIC
consortium) and used qualitative and quantitative (Item Response Theory/IRT) harmonization techniques to
estimate SCD prevalence.
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Results: The sample comprised 39,387 cognitively unimpaired individuals above age 60. The prevalence of
SCD across studies was around one quarter with both qualitative harmonization/QH (23.8%, 95%CI = 23.3–
24.4%) and IRT (25.6%, 95%CI = 25.1–26.1%); however, prevalence estimates varied largely between studies (QH
6.1%, 95%CI = 5.1–7.0%, to 52.7%, 95%CI = 47.4–58.0%; IRT: 7.8%, 95%CI = 6.8–8.9%, to 52.7%, 95%CI = 47.4–
58.0%). Across studies, SCD prevalence was higher in men than women, in lower levels of education, in Asian
and Black African people compared to White people, in lower- and middle-income countries compared to
high-income countries, and in studies conducted in later decades.
Conclusions: SCD is frequent in old age. Having a quarter of older individuals with SCD warrants further investigation
of its significance, as a risk stage for AD and other dementias, and of ways to help individuals with SCD who seek
medical advice. Moreover, a standardized instrument to measure SCD is needed to overcome the measurement
variability currently dominant in the field.
Keywords: Subjective cognitive decline, Prevalence, Epidemiology, Individual participant data, Data harmonization,
Cohort study
Background
In light of the projected increase of people living with de-
mentia all around the world, there is a strong interest in
early risk stages that may allow for early intervention or
the prevention of dementia [1]. Subjective cognitive de-
cline (SCD) has recently attracted renewed attention on
the assumption that it could be the first notable manifest-
ation in the preclinical stage of Alzheimer’s disease (AD)
and other dementias [2]. SCD refers to a self-experienced
decline in cognitive ability in comparison with a previously
normal status and without objective cognitive impairment
[3]. The updated AD research framework of the National
Institute on Aging and Alzheimer’s Association (NIA-AA)
now recognizes SCD within the cognitively unimpaired
stage on the cognitive continuum [4]. Thus, SCD is con-
sidered a risk stage for dementia. This is supported by evi-
dence from longitudinal epidemiological data that show
an increased risk for mild cognitive impairment (MCI)
and dementia in individuals with SCD [2].
Importantly, the subjective perception of declining
cognitive capacity can also emerge due to conditions
other than AD, for example as part of normal aging,
MCI, and in association with depression and anxiety [3].
Primarily, SCD is considered a symptom of preclinical
AD only in association with AD biomarkers; however,
another view is to consider SCD as a broader behavioral
phenotype [5] above and beyond preclinical AD that de-
fines a group of people being concerned about their
brain health. This is reflected in an increasing number of
individuals who seek medical advice because of SCD [6].
Despite the growing research interest in SCD, the con-
cept still faces methodological challenges regarding its
operationalization [7]. Historically, the field has lacked a
common terminology and definition since the initial de-
scription of a “forgetfulness phase” by Reisberg et al. in
1982 [8]. This resulted in the dissemination of a variety
of terms, e.g., subjective memory complaints, subjective
memory impairment, forgetfulness, subjective cognitive
impairment, or cognitive concerns—to name a few. This
hurdle has recently been cleared through the introduc-
tion of a consensus definition of SCD in preclinical AD
by the working group of the Subjective Cognitive De-
cline Initiative (SCD-I) [3]. A standard approach to
measure SCD, however, is still lacking [9]. In light of the
evolution of the concept, it is unsurprising that previous
findings on SCD epidemiology varied, including preva-
lence estimates. Early studies investigating more general
memory complaints reported prevalences between 22
and 56% in community-based samples [10]. Studies esti-
mating SCD prevalence based on the SCD-I criteria are
scarce, but there are some examples: In a sample repre-
senting the Greek population aged ≥ 65 years without
psychiatric conditions, 28% of the cognitively unim-
paired participants reported SCD [11]. In a German
sample of cognitively unimpaired individuals aged ≥ 75
years, SCD prevalence was 54% [12]. In Chinese resi-
dents aged 60 to 80 years, SCD prevalence ranged be-
tween 14 and 19% [13]. This, together with a lack of
standardized SCD assessment and variations in case defi-
nitions, explains variance in reported outcomes. Notably,
the occurrence of SCD has almost exclusively been stud-
ied in high-income countries (HIC), while evidence from
low- and middle-income countries (LMIC) is lacking.
The SCD-I emphasized the need for harmonized obser-
vational studies that can attenuate some of the limita-
tions associated with SCD operationalization [7].
Study aims
We aimed to estimate SCD prevalence in cognitively un-
impaired older individuals by applying uniform SCD cri-
teria to harmonized data from 16 diverse cohort studies
of aging. By doing so, we aimed to minimize the influ-
ence of both study level and individual level factors,
thereby enhancing the generalizability of findings [14].
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Moreover, as SCD prevalence may vary across sub-
groups, we aimed to examine differences in SCD preva-
lence according to sociodemographic (age, gender,
education, and ethnicity) and regional (country income)
factors as well as time (decade of study baseline) across
studies.
Methods
Contributing studies and participants
Cross-sectional population-based individual participant
data (IPD) were contributed by 16 member studies of
the Cohort Studies of Memory in an International Con-
sortium (COSMIC; https://cheba.unsw.edu.au/consortia/
cosmic/studies) [15] (Table 1; see Supplemental material
Table e-1 for key references). COSMIC brings together
international cohort studies of aging to foster cross-
cohort analyses on common factors for cognitive decline
and dementia. Study-based data were harmonized and
pooled. Baseline data were used for all studies except for
two that did not assess all variables needed for SCD clas-
sification until later waves, i.e., the Monongahela Valley
Independent Elders Survey (MoVIES) provided data for
wave 2 (2 years after baseline) and the Personality and
Total Health Through Life Project (PATH) for wave 3
(8 years after baseline). The initial sample included indi-
viduals aged at least 60 years and without a dementia
diagnosis (Table e-2). Drawing on a dementia-free sam-
ple was the default option as some studies excluded
prevalent dementia cases as per their study design. For
the current study, data represented 15 countries from
Africa, Asia, Australia, Europe, and North America.
Ethics
The Human Research Ethics Committee of the Univer-
sity of New South Wales approved this study (Ref:
HC17292). All contributing studies had previously ob-
tained approval from their respective ethics committees,
and it was standard that participants provided written
informed consent.
Demographics
Information included age, gender, education, ethnicity,
country income, and decade in which a study was con-
ducted. Education was provided as years for most studies.
For four cohorts (ActiveAging, Epidemiology of dementia
in Central Africa/EPIDEMCA, Etude Santé Psychologique
et Traitement/ESPRIT, Maastricht Aging Study/MAAS),
education data were provided as categories. For
harmonization purposes, categories were assigned discrete
year values based on the local education system as in-
formed by the study leaders. A fifth cohort (MoVIES) pro-
vided category data for educational levels for all
participants and values for years of education for 73.4% of
all participants. These data were used to calculate a mean
year value for each category that was assigned to individ-
uals missing education year data. For subgroup analysis
only, years of education were re-categorized according to
the UNESCO International Standard Classification of
Table 1 Contributing studies (n = 16)






Atma Jaya Cognitive & Aging Research ActiveAging Indonesia LMIC 2009 278
Cognitive Function & Ageing Studies CFAS UK HIC 1989–1991 12,457
Einstein Aging Study EAS USA HIC 1993 2154
Epidemiology of Dementia in Central Africa EPIDEMCA Republic of Congo,
Central African Republic
LIC/LMIC 2011–2012 1867
Etude Santé Psychologique et Traitement ESPRIT France HIC 1999–2001 2190
Invecchiamento Cerebrale in Abbiategrasso Invece.Ab Italy HIC 2010 1280
Korean Longitudinal Study on Cognitive Aging and Dementia KLOSCAD Korea HIC 2009–2012 6430
Leipzig Longitudinal Study of the Aged LEILA75+ Germany HIC 1997 1045
Long-term Research Grant Scheme - Towards Useful Aging LRGS-TUA Malaysia UMIC 2012–2013 2131
Maastricht Aging Study MAAS Netherlands HIC 1993 500
Monongahela Valley Independent Elders Survey MoVIES USA HIC 1987–1989 1276
Personality and Total Health Through Life Project PATH Australia HIC 2001 1965
Sasaguri Genkimon Study SGS Japan HIC 2011 2618
Singapore Longitudinal Ageing Studies II SLASII Singapore HIC 2003 2585
Sydney Memory and Ageing Study SydneyMAS Australia HIC 2005–2007 1037
Zaragoza Dementia Depression Project ZARADEMP Spain HIC 1994 4415
HIC high-income country, LIC low-income country, LMIC lower-middle income country, UMIC upper-middle income country
*According to World Bank classification at year/mean year of baseline assessment
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Education (ISCED) 2011 into pre-/primary education (0
to 5 years), secondary education (6 to 9 years), upper-/
post-secondary education (10 to 14 years), and tertiary
education (> 14 years) [16].
Ethnicity was recorded according to self-report, i.e., in
an open question format in the Cognitive Function &
Ageing Studies (CFAS) and according to pre-specified
categories in the Einstein Aging Study (EAS), the Long-
term Research Grant Scheme - Towards Useful Aging
(LRGS-TUA), MoVIES, and the Sydney Memory and
Ageing Study (MAS). All other studies did not assess
ethnicity. Therefore, participants’ ethnicity was assigned
as the majority ethnicity of the study sample as informed
by the study leaders. Due to the lack of data granularity
with regard to ethnic groups, analysis was based on three
major ethnic groups: Asian people, Black African people,
and White people.
Country income was categorized according to the World
Bank classification corresponding to the year or mean year in
which baseline assessments took place. It is based on the
gross national income per capita, i.e., low-, lower middle-,
upper middle-, and high-income country [17].
To account for a potential impact of time trends re-
garding dementia awareness, we furthermore considered
the decade, in which studies were initiated (< 1999,
2000–2009, > 2009).
Assessment of self-experienced decline in cognitive
capacity
Assessment of a self-experienced decline in cognitive cap-
acity varied across studies, though answers to all questions
were self-reported during face-to-face interviews, using
paper and pencil questionnaires (see Table e-3 for an
overview of instruments). Six studies used a single self-
developed question, seven studies used a battery of self-
composed questions, and one study used the Subjective
Memory Complaints Questionnaire (SMCQ) [18]. For two
studies (ActiveAging and Long-term Research Grant
Scheme - Towards Useful Aging/LRGS-TUA), the item
“Do you feel you have more problems with memory than
most?” from the Geriatric Depression Scale (GDS-15) was
used [19]. In PATH, the Informant Questionnaire on Cog-
nitive Decline in the Elderly (IQCODE) was administered
as self-report, including seven items that addressed
whether different facets of memory and recall had chan-
ged over time [20]. Data on all identified items were then
synthesized and harmonized.
One fundamental challenge of integrative data analysis
is the evaluation and statistical consideration of between-
sample heterogeneity. Since the majority of contributing
studies used multiple items to assess a self-experienced
decline in cognitive capacity, we followed two comple-
mentary strategies to prepare data.
Qualitative harmonization of items for a self-experienced
decline in cognitive capacity
The first harmonization strategy followed a qualitative
approach [21]. Authors SR and AP independently com-
pared all items assessing self-experienced decline in cog-
nitive capacity across studies and then selected and
harmonized them by matching semantically similar
items, i.e., if more than one item was available. Inter-
rater agreement was high (K = 0.97). The original scales
for all items were transformed, if necessary, to provide
binary responses of presence or absence of a self-
experienced decline in cognitive capacity. As a result, we
identified and harmonized one common item that brid-
ges the measurement of a self-experienced decline in
cognitive capacity across studies (we refer to this item as
“item 1”). Table e-3 shows the assessment of the selected
items underlying the harmonization of item 1 across
studies. Commonly, these items broadly addressed
whether the study participant had problems or difficul-
ties with memory; MAAS provided a single item asses-
sing cognitive failures. For six studies, only data on this
bridging item 1 was available. For the remaining ten
studies, information on additional items was available
and considered for harmonization. Overall, we were able
to identify and harmonize a total of 32 different items
for IRT analysis (Table e-4).
Quantitative harmonization of items for a self-
experienced decline in cognitive capacity
The second harmonization strategy followed a quantita-
tive approach in order to develop a measurement model
for both common and study-unique items. The goal was
to generate scale scores for a generic construct of self-
experienced cognitive decline, which is commensurate in
meaning and metric across studies and study subpopula-
tions [22]. In particular, we used the 2-Parameter Logistic
(2-PL) Item Response Theory (IRT) model as a psycho-
metric approach to evaluate measurement equivalence of
items across the 16 studies. IRT allows the localization of
both item difficulty and person characteristics on a com-
mon latent “trait” that represents self-experienced decline
in cognitive capacity, while controlling for between-study
heterogeneity of measurement. Higher difficulty values in-
dicate a higher likelihood of a positive response to a cer-
tain item [22]. First, we applied an automated bottom-up
stepwise item selection procedure to identify a core set of
items that builds the basis for IRT analysis [23]. The pro-
cedure revealed that 18 of the 32 items (see Table e-4)
form a unidimensional factor with acceptable scalability
(Loevinger’s Hij = 0.43) and good reliability (Cronbach’s
Alpha = 0.81). Inspection of parameters of the fitted 2-PL
IRT model (i.e., difficulty, discrimination), as well as the
evaluation of item characteristics curves, led to the exclu-
sion of two additional items with insufficient psychometric
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properties (item 2, item 5), resulting in a final IRT model
with 16 items with partial factorial invariance and the fol-
lowing fit indices: root mean square error of approxima-
tion = .02; comparative fit index = .87; Tucker Lewis
Index = .85; standardized root mean square residuals = .09,
indicating an only approximately acceptable model fit.
However, inspection of alternative models did not reveal a
better fitting model across the 16 contributing studies,
i.e. the presented IRT model represented the best fit. Fi-
nally, we dichotomized the predicted latent score obtained
from the final IRT model at theta = 0 to differentiate indi-
viduals with a higher likelihood of present symptoms from
those with lower estimated likelihood [24]. The cut of
theta = 0 was pre-specified prior to the analysis as there is
no gold standard to draw on and it may best separate
cases from non-cases as it represents the mean of the cali-
bration sample for the IRT model.
Cognitive impairment
The Mini-Mental State Examination (MMSE) was used to
assess cognitive impairment [25]. This was the default op-
tion as the MMSE was assessed in all but two studies, for
which MMSE scores could be derived from similar tests.
For the Einstein Aging Study (EAS), Blessed Information
Memory Concentration scores were converted to MMSE
scores using a validated formula [26, 27]. The formula was
based on correlational analysis of the scores of the two
tests in individuals with AD and both tests demonstrated
high test-retest reliability of r = .75 and above, thus show-
ing high consistency [27]. For the EPIDEMCA cohort,
Community Screening Interview for Dementia (CSI ‘D’)
scores were converted to MMSE scores using a co-
calibration table [28, 29]. The co-calibration table was de-
veloped for four commonly used tests of global cognitive
functioning, including the CSI ‘D’ and the MMSE, using
IRT based on cross-sectional data from three large (n >
1000) community-based studies of cognitive functioning
in old age [29]. Therefore, scores from one test can be dir-
ectly compared to scores on the other test.
Functional ability
Functional ability was based on the assessment of instru-
mental activities of daily living (IADL). Nine studies
used the Lawton and Brody IADL Scale [30]. Seven stud-
ies each used a different scale, though all had large over-
lap in key activities (e.g., food preparation, shopping).
All instruments are listed in Table e-5. For all studies,
higher scores indicated higher functionality (after reverse
scoring for EPIDEMCA and SydneyMAS).
Depressive and anxiety symptomatology
All studies contributed data for depression and 12 stud-
ies for anxiety (anxiety data were not collected in Acti-
veAging, Leipzig Longitudinal Study of the Aged/
LEILA75+, LRGS-TUA, and MoVIES). Data were har-
monized as per previous COSMIC reports, with all avail-
able information considered [31, 32]. Depression was
indicated by any of scale scores meeting cut-off, expert
diagnosis, self-report, treatment, or use of antidepressant
medication (Table e-6). Similarly, anxiety disorders were
indicated by any of scale scores meeting cut-off, self-
report, or the use of anxiolytics (Table e-7).
Operationalization of SCD cases
SCD cases were uniformly defined and operationalized
according to current criteria for SCD and followed rec-
ommendations on the implementation of SCD in re-
search, i.e., endorsement of a self-experienced decline in
cognitive capacity in the absence of objective cognitive
impairment (criterion 1), unimpaired functional ability
(criterion 2), exclusion of major depression (criterion 3),
and exclusion of anxiety disorder (criterion 4) [2, 7].
Endorsement of a self-experienced decline in cognitive
capacity and the presence or absence of major depres-
sion or anxiety disorder were determined as above.
Unimpaired cognitive functioning was operationalized
as a score higher than 1.5 SDs below the mean of the
study-based age-, gender-, and education-adjusted MMSE
score in order to differentiate individuals with and without
(mild) cognitive impairment. Likewise, unimpaired func-
tional ability was operationalized as a score higher than
1.5 SDs below the mean of the study-based age-, gender-,
and education-adjusted IADL scores.
Data analysis
Prevalence in our study was defined as the number of
SCD cases divided by the total number of cognitively un-
impaired individuals, and estimates for both the qualita-
tive harmonization (QH) and quantitative IRT
harmonization approach are presented as percentages
with 95% confidence intervals (95%CI). All estimates
were stratified by study and subsequently by demo-
graphic subgroups (age, gender, education, ethnicity,
country income, decade). Study-specific prevalence esti-
mates as well as subgroup-specific prevalence estimates
and corresponding tests regarding differences in educa-
tion, ethnicity, country income, and decade were ad-
justed for age and gender, using the total sample of all
16 studies included in the analysis as the standard popu-
lation. Gender differences were adjusted for age and vice
versa. This allowed for the direct comparison of preva-
lence estimates across studies and subgroups, including
different distributions of core sociodemographic vari-
ables [33]. Subgroup comparisons of proportions were
tested using Pearson’s chi-square test with Rao/Scott
correction. Overall prevalence estimates across studies
are reported as unstandardized, since data on standard
Röhr et al. Alzheimer's Research & Therapy          (2020) 12:167 Page 5 of 14
populations stratified by age and gender were not
available.
To illustrate the impact of the individual criteria to
quantify SCD cases, we show frequency rates criteria-wise,
i.e., cumulatively applying the four criteria for SCD.
A range of sensitivity analyses were performed. First,
an additional analysis was conducted with regard to IRT
results by excluding studies with only the bridging item
(“item 1”) available. Second, we inspected the contin-
gency of the results of the two harmonization strategies
(QH and IRT). Lastly, as the MMSE scores may have
limited sensitivity and specificity to differentiate unim-
paired cognitive performance from MCI [7], we con-
ducted a sensitivity analysis with a subset of studies (n =
10) that were able to provide neuropsychological test
scores on at least three out of four cognitive domains
(memory, language, processing speed and executive
function; see Table e-9 for an overview of contributing
studies and neuropsychological tests; harmonization pro-
cedure as in previous COSMIC studies [31, 32]). To es-
tablish unimpaired cognitive performance based on the
cognitive domains scores, the first step was to adjust test
scores for age, sex, and education, and for all interac-
tions between these variables using regression analyses
within each study. The adjusted test scores were then
transformed to z-scores using the mean and SD of the
study sample as normative values. Cognitive impairment
for each cognitive score was defined as performance of
more than 1.5 SDs below the mean within the relevant
study’s sample. To be classified cognitively impaired, this
had to be the case in at least one of the considered do-
mains. Otherwise, operationalization of SCD and statis-
tical analysis was identical to the MMSE-based
procedure.
Analyses were performed in Stata 15 MP (Stata Corp,
College Station, TX) and R version 3.5.0 [34].
Results
Sample
The initial sample comprised 44,228 dementia-free indi-
viduals aged at least 60 years. Inspection of the initial
sample led to the exclusion of 1037 (2.3%) individuals
due to study-based missing information on any of the 32
SCD items and 1049 (2.4%) individuals due to missing
information on demographics and/or MMSE. In
addition, 2755 (6.2%) individuals classified as cognitively
impaired were excluded, resulting in an analytical sam-
ple of 39,387 individuals (Table 2). The mean age of par-
ticipants in the analytical sample was 73.1 years (SD =
7.1; range = 60–105 years). The proportion of women
was 57.7%. Education was 9.1 years (SD = 4.4) on
average.
Prevalence of SCD in and across studies
Overall, both the QH and IRT approach robustly sug-
gested a SCD prevalence of roughly one in four in the
older population without cognitive impairment across
studies (QH 23.8% [95%CI = 23.3–24.4%]; IRT 25.6%
[95%CI = 25.1–26.1%]). Study-based age- and gender-
standardized SCD prevalence estimates varied largely,
ranging from 6.1% (95%CI = 5.1–7.0%) to 52.7%
(95%CI = 47.4–58.0%) for QH and 7.8% (95%CI = 6.8–
8.9%) to 52.7% (95%CI = 47.4–58.0%) for IRT. All study-
based SCD prevalence estimates according to QH and
IRT are shown in the last column in Tables 3 and 4,
respectively.
Proportions according to cumulative criteria application
The columns of Tables 3 and 4 show the proportions of
the incremental application of the four operationalization
criteria for SCD. There was a particular difference in pro-
portions between functional criteria (endorsement of a
self-experienced decline in cognitive capacity without ob-
jective cognitive impairment and functional ability) and
mood criteria (depressive and anxiety symptomatology).
When in addition to functional criteria depressive and
anxiety symptomatology were addressed, overall propor-
tions decreased from 30.5 to 23.8% (95%CI = 30.0–30.9%;
95%CI = 23.3–24.4%, respectively) in QH and from 34.5 to
25.6% (95%CI = 34.0–35.0%; 95%CI = 25.1–26.1%, respect-
ively) in IRT.
Prevalence of SCD according to age group and gender
across studies
The following subgroup results are based on IRT ana-
lysis, applying all four SCD criteria. Gender differences
were adjusted for age and vice versa. The subgroup re-
sults of the qualitative approach are detailed in Table e-
10. Overall, SCD prevalence was somewhat higher in
men compared to women (26.6% [95%CI = 25.7–27.4%]
vs. 24.9% [95%CI = 24.2–25.6%]; χ2(1) = 8.54; p = .003).
SCD prevalence significantly differed according to age
group (χ2(5) = 51.31; p < .001), which also applied when
stratified for gender (men: χ2(5) = 32.42; p < .001;
women: χ2(5) = 29.81; p < .001). SCD prevalence was
27.4% (95%CI = 25.8–28.9%) in ages 60–64 years, then
decreased to 23.2% (95%CI = 22.1–24.2%) in ages 65–69
years, thereafter increased to 24.5% (95%CI = 23.6–
25.5%) in ages 70–74 years, 27.9 (95%CI = 26.5–29.3%)
in ages 75–79 years, and 28.1% (95%CI = 26.2–30.0%) in
ages 80–84 years and 28.1% (95%CI = 25.7–30.9%) in
ages 85+ years. Overall, there was no clear pattern asso-
ciated with age, except for those aged 65–74 years gener-
ally having a lower prevalence than all other age groups.
Figure 1 additionally shows SCD prevalence according
to age groups stratified by gender.
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Prevalence of SCD according to education across studies
Age- and gender-standardized SCD prevalence signifi-
cantly differed according to level of education (χ2(3) =
68.37; p < .001). Individuals with pre-/primary education
had higher a prevalence of SCD (29.0%; 95%CI = 27.9–
30.2%) compared to individuals with secondary educa-
tion (25.0%; 95%CI = 24.1–25.9%), secondary upper/post
education (22.7%; 95%CI = 21.8–23.8%), and tertiary
education (26.4%; 95%CI = 24.8–28.0%).
Prevalence of SCD according to ethnicity across studies
Due to missing information on self-reported ethnicity,
this subgroup analysis was based on a subsample of n =
23,641 individuals. Age- and gender-standardized SCD
prevalence in White people (24.3%; 95%CI = 23.5–25.1%)
was significantly lower than in Asian people (27.2%;
95%CI = 26.3–28.1%) and Black African people (28.2%;
95%CI = 26.2–30.3%; Χ2(2) = 29.39; p < .001). Data avail-
ability did not allow including further ethnic groups.
Prevalence of SCD according to country income across
studies
Age- and gender-standardized SCD prevalence was sig-
nificantly associated with country income (χ2(2) = 9.56;
p < .001). The lower the country income, the higher the
SCD prevalence, increasing from 25.1% (95%CI = 24.5–
25.6%) in HIC to 27.4% (95%CI = 24.6–30.5%) in LMIC
to 29.3% (95%CI = 26.4–32.3%) in LIC.
Prevalence of SCD according to decade of study
conduction
Age- and gender-standardized SCD prevalence tended to
differ by decade (χ2(2) = 47.77; p < .001), showing an in-
crease over time from 22.4% (95%CI = 21.4–23.3%) be-
fore 1999, then 24.5% (95%CI = 23.1–25.9%) in the years
2000–2009 to 26.3% (95%CI = 25.9–27.4%) after 2009.
Sensitivity analysis
Results of the IRT-based sensitivity analyses of only
studies that used multiple items to assess a subjective
experience of cognitive decline are shown in Table e-8,
further supporting a pooled SCD prevalence of one in
four (26.1%; 95%CI = 25.4–26.7%).
The contingency of the results returned by the two
harmonization approaches was continuously high across
prevalence estimates. Using all four operationalization
criteria, SCD case classification based on “item 1” by QH
and IRT corresponded in 91.4% (Φ = 0.77) and in studies
with multiple items in 88.0% (Φ = 0.68) of all cases vs.
non-cases.
Sensitivity analysis utilizing cognitive domain scores
instead of MMSE scores to define unimpaired cognitive











ActiveAging Indonesia 260 68.60 (7.66; 60–97) 64.2 6.21 (4.73) Asian
CFAS UK 11,363 74.82 (6.64; 64–105) 59.2 10.03 (2.28) White
EAS USA 1950 78.53 (5.34; 64–100) 61.3 13.26 (3.59) White (66.6%), African
American/Black
(27.0%)
EPIDEMCA Republic of Congo, Central African
Republic
1736 72.74 (6.44; 65–99) 60.4 2.06 (3.86) Black African
ESPRIT France 2022 73.09 (5.50; 65–96) 58.0 12.34 (2.26) White
Invece.Ab Italy 1142 72.15 (1.28; 70–75) 53.9 7.00 (3.27) White
KLOSCAD Korea 5784 69.78 (6.48; 60–96) 55.7 8.37 (5.29) Asian
LEILA75+ Germany 875 81.51 (4.87; 75–99) 73.6 11.95 (1.81) White
LRGS-TUA Malaysia 1964 68.60 (5.94; 60–92) 50.2 5.47 (3.97) Asian
MAAS Netherlands 457 68.94 (6.02; 60–83) 49.5 9.47 (2.82) White
MoVIES USA 1188 74.06 (5.35; 66–97) 60.4 11.30 (2.48) White
PATH Australia 1469 70.60 (1.49; 68–74) 49.7 14.08 (2.67) White
SGS Japan 1948 73.44 (6.05; 65–93) 58.0 11.10 (2.50) Asian
SLASII Singapore 2364 69.02 (6.71; 60–94) 60.7 5.41 (4.17) Asian
SydneyMAS Australia 966 78.85 (4.82; 70–91) 55.2 11.63 (3.49) White
ZARADEMP Spain 3899 73.15 (9.20; 60–102) 56.5 7.18 (3.83) White
Total N/A 39,387 73.07 (7.08; 60–
105)
57.7 9.13 (4.43) N/A
M mean, N/A not applicable, R range, SD standard deviation
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function was based on a subset of ten studies. Results of
the qualitative approach are presented in Table e-11 and
of the quantitative/IRT approach in Table e-12. Table e-
13 juxtaposes SCD prevalence estimates across studies
for both the MMSE-based and cognitive domain scores-
based operationalization of unimpaired cognitive per-
formance (quantitative approach: 1.48% diff; qualitative
approach: 0.80% diff.)
Discussion
We estimated the prevalence of subjective cognitive de-
cline (SCD) by applying uniform criteria to harmonized
individual participant data (IPD). Data represented 16
international population-based cohort studies from 15
countries with over 39,000 individuals at least 60 years
old. Across studies, qualitative harmonization (QH) and
quantitative harmonization using Item Response Theory
(IRT) both robustly suggested a SCD prevalence of
roughly one quarter (23.8% and 25.6%) in cognitively un-
impaired older individuals. Still, prevalence estimates
varied largely between studies (QH 6.1–52.7%; IRT 7.8–
52.7%). However, applying uniform criteria for SCD
operationalization to harmonized data helps to increase
comparability of estimates across studies. This is a
strength of our study as SCD assessment greatly differed
between cohorts and different measurements are known
to be associated with outcome variance [35]. Indeed, dif-
ferences in prevalence estimates are directly associated
with test accuracy, and the majority of the items the co-
horts used to measure self-experienced decline in cogni-
tive capacity were not psychometrically evaluated. Used
in isolation, these potentially imperfect items may give
false-positive or false-negative results, resulting in biased
prevalence estimates. As the original studies contributing
to this work did not previously inspect SCD prevalence
in their samples, we cannot, however, determine whether
the application of uniform criteria to harmonized data
would have reduced SCD prevalence variation between
cohorts. A previous COSMIC study on MCI prevalence
using such methods suggested this is the case [36]. Add-
itionally, IRT analysis allowed heterogeneity between
studies to be addressed statistically, by selecting a set of
items that form a unidimensional scale, thus giving con-
fidence that all items measured one construct. Hence,
our study suggests that the prevalence of SCD in cogni-
tively unimpaired older individuals is banded around
25%, which may give a more accurate idea of SCD
prevalence than estimates of single studies, which are
Table 3 Study-based age- and gender-standardized prevalence estimates for subjective cognitive decline (SCD; last column) and
cumulative frequency estimates for the stepwise application of SCD operationalization criteria according to qualitative harmonization
Study SCD operationalization criteria
Criterion 1
Endorsement of a self-experienced decline









ActiveAging 27.98 (21.44–34.52) 25.81 (19.41–32.20) 25.73 (19.36–32.10) N/A
CFAS 17.04 (15.45–18.64) 15.59 (14.00–17.18) 12.73 (11.41–14.05) 6.34 (5.57–7.20)
EAS 15.84 (12.57–19.10) 13.82 (10.90–16.73) 15.23 (10.95–19.51) 12.05 (5.80–18.30)
EPIDEMCA 50.52 (48.36–52.69) 47.74 (45.51–49.98) 25.83 (23.80–27.86) 23.86 (21.93–25.79)
ESPRIT 18.17 (16.52–19.82) 16.60 (15.02–18.18) 13.36 (11.92–14.80) 10.35 (9.11–11.60)
Invece.Ab 14.60 (11.63–17.56) 14.02 (10.89–17.16) 12.31 (9.43–15.18) 10.76 (8.28–13.23)
KLOSCAD 63.65 (62.28–65.02) 58.02 (57.88–59.46) 42.25 (40.82–43.68) 42.27 (40.90–43.66)
LEILA75+ 12.88 (11.65–14.12) 11.70 (10.48–12.92) 9.80 (8.64–10.96) N/A
LRGS-TUA 51.23 (48.15–54.31) 47.39 (44.32–50.47) 46.84 (43.80–49.87) N/A
MAAS 65.26 (60.33–70.20) 60.52 (55.35–65.69) 54.97 (49.43–60.50) 52.70 (47.43–57.96)
MoVIES 32.82 (30.35–35.32) 30.45 (28.01–32.90) 27.27 (24.89–29.65) N/A
PATH 8.95 (7.89–10.01) 8.23 (7.21–9.26) 7.34 (6.36–8.33) 6.06 (5.13–6.99)
SGS 18.47 (16.82–20.13) 16.52 (14.93–18.10) 10.24 (8.94–11.55) 9.91 (8.64 (11.18)
SLASII 12.16 (10.53–13.79) 10.82 (9.27–12.36) 10.28 (8.78–11.78) 9.89 (8.50–11.28)
SydneyMAS 42.77 (40.49–45.04) 39.10 (36.70–41.51) 32.58 (30.14–35.01) 26.98 (24.55–29.40)
ZARADEMP 44.68 (42.98–46.38) 42.04 (40.31–43.77) 29.42 (27.77–31.06) 28.12 (26.50–29.74)
Total* 33.03 (32.56–33.49) 30.46 (30.01–30.92) 24.08 (23.65–24.51) 23.83 (23.29–24.36)
95%CI 95% confidence interval, N/A not available
*Unstandardized
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potentially more heavily influenced by measurement
issues.
Our results support the notion that SCD is frequent in
old age. It is most likely that only a proportion of these
cases reflect pathological change due to AD or other de-
mentias. The list of non-neurodegenerative conditions
that can lead to subjective decline in cognition is long,
including, apart from major depression and anxiety, nor-
mal aging, various psychiatric, neurologic and medical
disorders, substance abuse and medication, as well as
personality and cultural factors [3]. The current SCD re-
search definition cannot rule out all other causes, and
this is likely reflected in the range of prevalence esti-
mates we found. In this regard, it is interesting to note
the difference it made when major depression and anx-
iety disorders were considered as exclusion criteria in
addition to cognitive impairment and functional inability
(which some studies have only used), reducing estimates
from roughly one third to one quarter. While the exclu-
sion of depression and anxiety disorder is accepted in
the criteria, it does highlight the impact criteria can have
on prevalence estimates. In addition, many of the above
named conditions are associated with an increased risk
for cognitive decline and dementia themselves. Vice
versa, specific symptoms, especially depressive and anx-
iety symptoms, can also be a consequence of neuro-
pathological change or co-occur, so that the relationship
between SCD, these conditions, and neurodegeneration
is more complex [3]. In this regard, it seems useful to
explore SCD in conjunction with other behavioral symp-
toms [37]. Like SCD, problems with mood, anxiety,
drive, perception, sleep, appetite, agitation, and aggres-
sion can be precursors to cognitive decline and demen-
tia, as summarized in the construct mild behavioral
impairment (MBI) [38]. Future investigations could link
the two behavioral concepts rather than studying them
independently.
Age- and gender-standardized SCD prevalence differed
regarding sociodemographic factors. We found slightly
higher SCD prevalence in men compared to women.
The literature on gender differences in SCD prevalence
is inconsistent, some reporting higher prevalence in
women [39, 40], others in men [41], or no difference
[42]. For both men and women, SCD prevalence differed
Table 4 Study-based age- and gender-standardized prevalence estimates for subjective cognitive decline (SCD; last column) and
cumulative frequency estimates for the stepwise application of SCD operationalization criteria according to quantitative
harmonization/Item Response Theory (IRT) modeling
Study SCD operationalization criteria
Criterion 1
Endorsement of a self-experienced decline








Prevalence estimates in % (95%CI)
ActiveAging 27.97 (21.43–34.51) 25.80 (19.40–32.20) 25.73 (19.36–32.10) N/A
CFAS 23.44 (21.77–25.12) 21.59 (19.91–23.26) 17.78 (16.36–19.20) 9.60 (8.63–10.58)
EAS 50.41 (45.20–55.62) 46.06 (41.06–51.06) 38.71 (34.07–43.34) 25.91 (19.33–32.48)
EPIDEMCA 56.28 (54.18–58.38) 53.02 (50.83–55.21) 30.64 (28.51–32.77) 28.41 (26.38–30.44)
ESPRIT 31.26 (29.34–33.18) 28.76 (26.89–30.63) 23.97 (22.20–25.74) 18.94 (17.36–20.51)
Invece.Ab 14.61 (11.64–17.58) 14.03 (10.90–17.17) 12.32 (9.44–15.20) 10.77 (8.28–13.26)
KLOSCAD 55.51 (54.09–56.92) 50.55 (49.10–52.00) 36.01 (34.62–37.40) 35.97 (34.62–37.31)
LEILA75+ 12.89 (11.66–14.13) 11.71 (10.49–12.94) 9.81 (8.65–10.97) N/A
LRGS-TUA 51.23 (48.15–54.31) 47.40 (44.32–50.47) 46.84 (43.80–49.87) N/A
MAAS 65.26 (60.32–70.20) 60.52 (55.34–65.69) 54.97 (49.43–60.51) 52.70 (47.43–57.98)
MoVIES 29.39 (26.97–31.81) 27.20 (24.83–29.57) 23.87 (21.59–26.15) N/A
PATH 11.68 (10.50–12.86) 10.76 (9.62–11.90) 9.63 (8.54–10.73) 7.83 (6.80–8.87)
SGS 18.47 (16.81–20.12) 16.51 (14.93–18.09) 10.24 (8.93–11.54) 9.91 (8.64–11.18)
SLASII 25.48 (23.37–27.59) 22.87 (20.83–24.91) 22.17 (20.16–24.18) 21.18 (19.31–23.05)
SydneyMAS 45.81 (43.41–46.39) 42.72 (40.48–44.95) 35.87 (33.55–38.19) 29.88 (27.54–32.22)
ZARADEMP 44.69 (42.99–46.39) 42.04 (40.32–43.77) 30.64 (28.51–32.77) 28.12 (26.50–29.74)
Total* 37.32 (36.85–37.79) 34.49 (34.02–34.97) 27.75 (27.31–28.20) 25.60 (25.06–26.14)
95%CI 95% confidence interval, N/A not available
*Unstandardized
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by age; however, without a clear pattern. This is similar
to MCI prevalence, but different to dementia prevalence
that shows an increase with aging [36].
SCD prevalence was highest in individuals with less
education, which is in line with a previous study [43].
Hao et al. suggested that low education may be a risk
factor for SCD, being associated with a higher likelihood
of progression to MCI [13]. While the prevalence de-
creased with increasing levels of education, there was a
tendency to increase again among those with the highest
education levels. In general, higher educational attain-
ment is thought to provide resilience against neuropath-
ology [44]. This could be expected to lead to a delay in
symptom onset and therefore, potentially, a lower SCD
prevalence associated with higher levels of education.
However, our finding of higher SCD prevalence in those
with the highest education suggests otherwise and pos-
sibly points to increased awareness of or alertness to
subtle cognitive changes in this group.
Regarding ethnicity, we found higher SCD prevalence
in Asian and Black African people compared to White
people, which is supposedly associated with country in-
come as ethnic group definition was very broad due to a
lack of ethnic data granularity across studies. With re-
gard to results from other studies, a US study reported
similar levels of SCD for African American people and
White people [45], whereas in another US study SCD
was lower in Asian people compared to White people
and highest in Black American people and American In-
dian people [43]. The results of our study, however,
should be interpreted with caution as data on ethnicity
were limited and may not be representative. SCD preva-
lence and ethnicity is otherwise a largely unexplored
topic.
SCD prevalence was lower in HIC compared to LMIC.
From an ecobiopsychosocial perspective, this supports
the notion that environments with higher socioeconomic
resources (e.g., better health care, better educational op-
portunities, better lifestyle infrastructure) may be benefi-
cial for population health [46]. Indeed, dementia
incidence has been observed to have slightly declined in
recent decades in Western high-income countries, sup-
porting such an assumption [47]. Opposed to that, we
found a trend of increasing SCD prevalence over de-
cades from before 1999 to after 2009. On the one hand,
this could be attributed to increasing public health
awareness regarding dementia, or, on the other hand, to
the fact, that latter data included more studies from
LMIC whereas early studies were exclusively from HIC.
However, as much of the increase in numbers of people
living with dementia takes place in LMIC [48], there
may be indeed a trend towards increasing SCD.
Regardless of causes or consequences, SCD is a serious
issue for individuals who experience it. SCD has been as-
sociated with concerns [49], lower health-related quality
of life [50], increased help-seeking behavior and health
care utilization [51]. Thus, SCD has a negative impact
on the individual, but also on society through creating
additional costs [52]. Having roughly one quarter of the
cognitively unimpaired older population experiencing
SCD poses the question “what to do about it?.” A sys-
tematic review and meta-analysis of interventions for
Fig. 1 SCD prevalence according to age groups and gender in older individuals (≥ 60 years) without cognitive impairment across international
cohort studies (percentages). Estimates are based on Item Response Theory (IRT) analysis
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SCD targeting well-being, meta-cognition, and/or object-
ive cognitive performance reported a lack of high-quality
research, but nevertheless found that psychological inter-
ventions may be beneficial for well-being and meta-
cognition in SCD, though not for cognitive performance
[52]. Furthermore, the same study reported a lack of evi-
dence regarding lifestyle and pharmacological interven-
tions. The SCD-I recently argued in support of tailored
diagnostic processes that identify underlying medical con-
ditions in individuals with SCD who present to physicians
[6]. If no cause can be identified, they suggest to inform
about SCD and dementia risk. From there, a watch and
wait strategy could be adopted. A comprehensive ap-
proach to deal with SCD, if no treatable underlying condi-
tion can be identified, is perhaps education about
modifiable health and lifestyle factors for brain health. In-
creasing evidence highlights that, among other factors, im-
proved management of diabetes, hypertension, and
obesity, as well as proactive lifestyle behaviors regarding
physical, cognitive, and social activity, can promote brain
health and may mitigate dementia risk [53].
Limitations
We were able to uniformly operationalize SCD across
studies according to current guidelines on SCD defin-
ition criteria [3, 7]; however, there may be factors not
considered in these criteria that influence prevalence es-
timates of SCD. From this perspective, our reported
SCD prevalence may be an overestimate. The MMSE
has been criticized for having limited sensitivity and spe-
cificity in differentiating between unimpaired and mildly
cognitively impaired performance [7]. Thus, SCD preva-
lence estimates based on cognitive performance derived
from MMSE scores could lead to an underestimation of
prevalence. Therefore, we performed a sensitivity ana-
lysis based on a subset of studies that were able to pro-
vide more comprehensive neuropsychological test
scores. In comparison, SCD prevalence estimates across
studies hardly differed, which strengthened the confi-
dence in the prevalence estimates utilizing MMSE
scores. However, where possible, preference should be
given to sensitive and specific tests.
Regarding IRT-based estimation of prevalence, we were
not able to pre-specify a cutoff other than theta = 0 to dif-
ferentiate between SCD cases and non-cases, as a gold
standard was not available. Moreover, fit indices of our
IRT model indicated room for improvement, which
should be considered when possibly developing a stan-
dardized measurement of SCD. Though we were able to
methodologically tackle heterogeneity in SCD measure-
ment across studies, estimates for individual studies are
likely influenced by the type of questions asked. This
could be one of the reasons for the large differences in
prevalence across the studies, and calls for a standardized
and psychometrically sound instrument for SCD. Also,
many items to assess a self-experience in cognitive cap-
acity did not cover perceptions of change over time; the
majority instead asked about current problems with mem-
ory—an acknowledged limitation in SCD research. Future
studies may also explore how study-based characteristics
beyond age and gender contribute to SCD prevalence vari-
ation across studies. Ultimately, only standardized and
valid SCD measurement will overcome these limitations,
and the SCD field should focus on the development of
such an instrument. Our IRT-based item analysis can pro-
vide useful information for this. For now, the comparable
results from two complimentary approaches to estimate
SCD prevalence across a set of diverse studies, further
supported by similar results from sensitivity analyses, pro-
vide a more accurate picture of SCD occurrence.
Conclusions
One in four cognitively unimpaired individuals above 60
years of age is estimated to experience and report SCD.
However, SCD is likely to indicate a pre-stage of AD or
other dementing disorders in only the minority of cases.
Nevertheless, the frequent occurrence of SCD warrants
further research of its significance for dementia, and, im-
portantly, on ways to manage SCD in clinical practice.
The development and application of a standardized
measure to assess SCD is imperative to further our un-
derstanding of SCD.
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